Stay updated on XEN1101 vs Placebo in Focal-Onset Seizures Clinical Trial
Sign up to get notified when there's something new on the XEN1101 vs Placebo in Focal-Onset Seizures Clinical Trial page.

Latest updates to the XEN1101 vs Placebo in Focal-Onset Seizures Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about the X-TOLE3 Phase 3 clinical trial for XEN1101, which included eligibility criteria and study design, while adding a new revision number and collaborators.SummaryDifference21%
- Check29 days agoChange DetectedThe page now indicates that the study has increased from 65 to 66 locations, and it includes a new location in Brussels, Belgium. Additionally, the revision number has been updated from v2.14.3 to v2.14.4.SummaryDifference1%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a more recent last update date (2025-03-25).SummaryDifference0.2%
- Check66 days agoChange DetectedThe page now lists 65 study locations, including new sites in Belgium, Germany, and Italy, and updates the trial date to 2025-03-03. The previous date of 2025-02-06 and the count of 62 locations have been removed.SummaryDifference2%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to XEN1101 vs Placebo in Focal-Onset Seizures Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XEN1101 vs Placebo in Focal-Onset Seizures Clinical Trial page.